- Home
- ABVC vs ICCM Comparison
ABVC vs ICCM Comparison
Compare ABVC & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- ICCM
- Stock Information
- Founded
- ABVC 2015
- ICCM 2006
- Country
- ABVC United States
- ICCM Israel
- Employees
- ABVC N/A
- ICCM N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- ICCM
- Sector
- ABVC Health Care
- ICCM
- Exchange
- ABVC Nasdaq
- ICCM Nasdaq
- Market Cap
- ABVC 52.1M
- ICCM 61.1M
- IPO Year
- ABVC N/A
- ICCM N/A
- Fundamental
- Price
- ABVC $3.30
- ICCM $0.90
- Analyst Decision
- ABVC
- ICCM Strong Buy
- Analyst Count
- ABVC 0
- ICCM 1
- Target Price
- ABVC N/A
- ICCM $2.00
- AVG Volume (30 Days)
- ABVC 223.6K
- ICCM 2.8M
- Earning Date
- ABVC 08-13-2025
- ICCM 08-13-2025
- Dividend Yield
- ABVC N/A
- ICCM N/A
- EPS Growth
- ABVC N/A
- ICCM N/A
- EPS
- ABVC N/A
- ICCM N/A
- Revenue
- ABVC $391,242.00
- ICCM $2,787,000.00
- Revenue This Year
- ABVC $735.18
- ICCM $75.27
- Revenue Next Year
- ABVC N/A
- ICCM $129.39
- P/E Ratio
- ABVC N/A
- ICCM N/A
- Revenue Growth
- ABVC 186.84
- ICCM N/A
- 52 Week Low
- ABVC $0.40
- ICCM $0.48
- 52 Week High
- ABVC $5.48
- ICCM $1.66
- Technical
- Relative Strength Index (RSI)
- ABVC 56.53
- ICCM 44.94
- Support Level
- ABVC $2.90
- ICCM $0.70
- Resistance Level
- ABVC $3.06
- ICCM $0.86
- Average True Range (ATR)
- ABVC 0.28
- ICCM 0.06
- MACD
- ABVC 0.00
- ICCM -0.01
- Stochastic Oscillator
- ABVC 91.92
- ICCM 53.74
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.